Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elite always has the shareholders as top priority. This is why there are a billion shares outstanding. Nasrat wants every man, woman and child in China to be able to own a share. We’re almost there…
Anything below 120F in NJ is too cold for a decent PR.
Great to hear, thanks for sharing. It is one data point, but good to hear. Hopefully we also go generic Vyvanse and Concerta route down road.
Wouldn’t this be retail pharmacies raising the prices, not the mfr or distributor?
This could hurt Adderall long term as it could be shifting customers to other stimulants available today that feel that their perceived risk of drug being out of stock is mitigated.
The poster didn’t say $20B company. Stock could go to $20 after counting for a sizeable R/S.
Elite would not want to work with Amazon. They will suck out every penny of margin that they can. Not worth it. I’d rather focus on larger profit opportunities.
Fershizzling out. Small spike on no news is absolutely going to come right back down.
Perhaps even a high likelihood there.
Day shift wording is common for 9-5 jobs if there are no other shifts. This has been standard for the last 20 years that I have seen.
Elite has been trying to hire similar roles for months.
That transition is the biggest concern by far. The good thing is they have the cash from the term loan they can use, but will it be a big enough runway? TBD on that and whether R&D will need to be put on hold again while tent poles are put back up.
Ignorance is bliss for those ignoring reality of the situation. Psst, there is no manipulation.
A whole 800 shares short? Lol
What do you mean, Nasrat was sold too. ??
Inventory liquidation is completely different from a business liquidation that was stated in 10K.
I don’t even need to look at that one to know that it was well before Nasrat entered the picture.
The word “merge” might be used, but there has never been an S-4 filing. That is just Nasrat’s wording of choice for his unloading of crap products to Elite for hundreds of millions of shares.
Thought Treppel had to sell out his entire ownership. Thx for clarifying.
Jerry Treppel, the last chairman, sold all his shares at much nicer price. Kudos to him and his barking dog.
Lannett also has Concerta for ADHD as well that is not made by Elite. Concerta is a much bigger market.
Unless there are long term investment fund that will buy into the stock from active IR outreach very few will care or know about this company and the price per share will fall. That should be expected. This is one instance when it’s critical to have a solid IR strategic plan to execute.
I’d like to see the generic Oxy do the speaking.
Any transition to NASDAQ had better be a follow to heavy external IR presence at conferences, roadshows, etc to get the name out. Otherwise, Elite will get indexes to buy in, larger short term funds that will trade, but no long term fund ownership. Would be nice to see sell-side coverage started if they can get a couple larger drugs approved and launched. Long term holders are needed to provide share price stability.
I scratch your back if you scratch mine. This is the model of far too many BODs, whether a million or multi-billion company.
My thought is that the company needs to get away from issuing anything other than options. Company can pay out his bonus in cash in lieu of stock. Same with the deadbeat BOD.
Options are how most public companies align shareholder interests with management financial incentives. In Elite’s case, the CEO was paid in stock to slow cash burn. This is no longer needed. In addition, the CEO used to occasionally buy shares on the open market. This hasn’t happened for many years at even further depressed prices we have today, which says something in itself. Since the company only uses grants for mgmt/BOD vs options I would be really concerned if shares were being sold, but they aren’t, meaning shares have been accumulated. However, by not using options, shareholders continue to get ripped a new one from continued stock dilution (grants and bonus payouts) while the stock price doesn’t rise and incentives given are clearly not aligning with or benefiting shareholders, allowing stock grant receivers to accumulate more at a depressed price.
Nasrat knows this, which is why he isn’t going the options route. His end goal is a sale of the company and he wants the biggest piece of that pie, however big or small that price will be.
Lol KK can’t sell much until after Lannett agreement ends. Bulk of revenue is with Adderall products that are locked up until 4/1. Don’t expect any big changes in next couple quarterly earnings calls, Feb & Jul as those are reporting business pre-Lannett split.
Pre-profitability the company was going to be the initial leader in opioid deterrent technology, which had the potential of a much larger revenue than what we’re doing today. Adderall ER was last decent drug and it was basically a failure to launch and that was almost 3 years ago. Pipeline & R&D has been stalled since then due to pandemic, but shares to CEO were not. $12M drugs continue to have Elite limp along and we can always continue the ANDA sell off strategy.
Yes, as in there is extremely high likelihood Elite spent much more. $300K would be an absurdly low cost with current state.
Agreed. With the recent sale of Vigabatrin to chalk up another ANDA sale, investors are in the dark about what Elite will keep vs sell off. I can’t imagine they only spent $300K each on all ANDAs sold off in the past. It’s as if mgmt enjoys going in circles and wasting shareholder money, but I’m sure it’s all for the sake of gaining experience for Elite.
Settlement was to be finalized last year that was about $500K each.
These days popcorn farts do have a faster launch time. Margin profile is questionable though.
They were claiming it the day before Vigabatrin ANDA sale + 3-year deal, but that’s almost to the level of peanuts.
Well what? Stock price is still in the crapper. It gets hit each year by tax loss selling from those that expect this to be the year and it just keeps sinking…
Be sure to share the news with Elite too.
Options would be nice to ensure they are of value and correlated to stock value growth or are worthless.
What is reported in 10K does not equate to being communicated in conference calls, however, CEO signs off on 10K personally.
Doubtful, but still up in the air
At some point I expect Nasrat’s strategy will include the combination of both dongs. Whether both together will create accretive value to Elite is questionable at best, but Nasrat would certainly benefit the most. Two dongs don’t make a right.
Simple answer. A company can be CFP, but investors are questioning the ability for the company to produce meaningful future value to shareholders. Also, the company also has a billion shares outstanding and has diluted heavily. There may also be concerns regarding the transition away from Lannett (e.g., need to raise cash to survive if transition doesn’t go as well as expected).
Building confidence is as simple as doing what management says they will do. If they do, stock rises as confidence is built in investment community. Don’t do it and blindside shareholders will decimate any stock, regardless if profitable.
How many times have Elite’s shareholders been surprised with news to the downside?
Saying one will execute X, Y & Z is far different from actually doing so. Proof is in the pudding or rather the applesauce that we can take with our SequestOx. Oh wait…
Mikah is winding down…
No one will stop us not even the FDA…
We will get to NASDAQ (said several years ago)…
The stock will not go to 3 cents…
Again, the ability to execute is what builds credibility with the investment community. Words without substance are meaningless. Q1 financial results will speak for themselves.